Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
